UITM-CaixaResearch

Home Tag

Copia de Copia de Copia de Banner web VHIO (12)

Preliminary results from a first-in-human phase 1/2 trial show promise of novel BiDAC ™ degrader designed to overcome treatment resistance in solid tumors

Presented today at the ESMO Congress 2024* by Maria Vieito, Medical Oncologist at the Vall d’Hebron University Hospital, CORE Phase…

Dra. Elena Garralda con bata VHIO, fondo difuminado

UITM-CaixaResearch presents promising results from the first clinical trial of an innovative next-generation antibody in patients with advanced solid tumours, especially in melanoma

Initial data from the first phase 1 trial of the bispecific antibody FS222 demonstrate that it is a drug with…

portada podcast cancer360 VHIO

Launch of a new Cancer360’s chapter to celebrate Clinical Trials World Day

Coinciding with the celebration on May 20 of the Clinical Trials World Day, this Monday the fifth chapter of the…

1 2 3